1. Home
  2. RUM vs STOK Comparison

RUM vs STOK Comparison

Compare RUM & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rumble Inc.

RUM

Rumble Inc.

HOLD

Current Price

$4.98

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$32.74

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RUM
STOK
Founded
2013
2014
Country
United States
United States
Employees
135
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
RUM
STOK
Price
$4.98
$32.74
Analyst Decision
Hold
Strong Buy
Analyst Count
1
10
Target Price
$10.00
$39.20
AVG Volume (30 Days)
1.8M
807.3K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
92.73
EPS
N/A
N/A
Revenue
N/A
$184,420,000.00
Revenue This Year
$209.98
N/A
Revenue Next Year
$40.99
$82.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
404.50
52 Week Low
$4.62
$5.35
52 Week High
$10.99
$40.22

Technical Indicators

Market Signals
Indicator
RUM
STOK
Relative Strength Index (RSI) 42.74 47.41
Support Level $4.67 $32.70
Resistance Level $7.02 $35.63
Average True Range (ATR) 0.23 2.38
MACD -0.00 -0.23
Stochastic Oscillator 40.47 53.03

Price Performance

Historical Comparison
RUM
STOK

About RUM Rumble Inc.

Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: